LSBC Q4 Revenues Down Slightly; R&D Costs Up 87 Percent | GenomeWeb

NEW YORK, Feb 1 – Large Scale Biology's fourth quarter revenues decreased slightly from a year ago, the company reported Thursday. LSBC attributed the drop in revenue, from $5.9 to $5.7 million, primarily to decreased development funding from Dow Chemical and Dow AgroSciences.

Higher R&D costs in the fourth quarter of 2000 compounded the drop in contract funding from Dow, the company said. Compared to the year-ago fourth quarter, R&D expenditures were up 87 percent to $4.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.